Multiple endogenous metalloenzymes and bone mineral

"Multiple endogenous metalloenzymes and bone mineral" is a composite target designation primarily used to describe the non-antimicrobial pharmacological actions of tetracycline-class antibiotics [1]. The metalloenzyme component predominantly includes matrix metalloproteinases (MMPs), such as MMP-8 and MMP-9, which are essential for extracellular matrix degradation and tissue remodeling [2][3]. Tetracyclines exert their inhibitory effect on these enzymes by chelating the catalytic zinc and structural calcium ions required for their activity [3]. This mechanism is therapeutically exploited in the treatment of chronic inflammatory conditions like periodontitis and rosacea, where excessive MMP activity leads to tissue destruction [2]. The bone mineral component refers to hydroxyapatite, the primary inorganic constituent of bone and dental tissues [4]. Tetracyclines possess a high affinity for the calcium ions within the hydroxyapatite lattice, leading to their permanent sequestration in calcifying tissues [4][5]. While this binding allows for the use of tetracyclines as fluorescent markers in bone research, it also results in significant clinical side effects, such as permanent tooth discoloration and potential inhibition of bone growth in pediatric patients [5]. Consequently, this target profile highlights both the pleiotropic therapeutic potential and the specific developmental safety concerns associated with the tetracycline drug class [1][5]. Sources: [1] DrugBank Online (DB00759); [2] Golub et al. (1998) Dental Clinics of North America; [3] Griffin et al. (2010) American Journal of Physiology; [4] Sanchez et al. (2004) International Journal of Dermatology; [5] StatPearls (Tetracycline).

Other names

Matrix metalloproteinases and hydroxyapatiteMMP and bone matrixMetalloenzyme-bone mineral complex

Inhibition of metalloenzymes through chelation of catalytic metal ions and sequestration in bone mineral via calcium binding.